SCHEMBL11923297

SCHEMBL11923297

COc1cccc(N(C(=O)c2cnc(N3CCCCC3)nc2-c2ccccc2Cl)C2CCOCC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 2/20 0.41
▸ PIK3CA P42336 2/20 0.41
▸ CAMK1D Q8IU85 2/20 0.39
▸ MAPT P10636 2/20 0.36
▸ OPRM1 P35372 1/20 0.36
▸ CNR2 P34972 2/20 0.36
▸ CNR1 P21554 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11923203 0.95 GPBAR1 (0.42) GPBAR1PIK3CACAMK1DMAPTOPRM1
SCHEMBL11923182 0.95 GPBAR1 (0.42) GPBAR1PIK3CACAMK1DMAPTOPRM1
SCHEMBL8267650 0.94 GPBAR1 (0.42) GPBAR1PIK3CACAMK1DMAPTOPRM1
SCHEMBL11923168 0.94 GPBAR1 (0.42) GPBAR1PIK3CACAMK1DMAPTOPRM1
SCHEMBL11923186 0.91 PDE4B (0.38) PIK3CAMAPTOPRM1ALDH1A1CYP1A2
SCHEMBL11923292 0.86 ALDH1A1 (0.41) PIK3CAALDH1A1CYP1A2TSHRHSD17B10
SCHEMBL11923243 0.85 FFAR1 (0.39) CAMK1DMAPTOPRM1CYP1A2TSHR
SCHEMBL8267722 0.85 FFAR1 (0.39) CAMK1DMAPTOPRM1CYP1A2TSHR
SCHEMBL8267732 0.85 ALDH1A1 (0.40) PIK3CAALDH1A1CYP1A2TSHRHSD17B10
SCHEMBL8266787 0.85 ALDH1A1 (0.41) PIK3CAALDH1A1CYP1A2TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546414-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-01 — — US disclosed
US-8546414-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-01 — — US disclosed
US-20120270318-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-25 — — US disclosed
US-20120270318-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-25 — — US disclosed
US-8236815-B2 Ion channel modulators and methods of uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-07 — — US disclosed
US-8236815-B2 Ion channel modulators and methods of uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-07 — — US disclosed
US-7767680-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-03 — — US disclosed
US-7767680-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-03 — — US disclosed
US-20100184753-A1 Ion Channel Modulators and Methods of Uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-22 — — US disclosed
US-20100184753-A1 Ion Channel Modulators and Methods of Uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184753-A1 Ion Channel Modulators and Methods of Uses CACNA1G, CACNA1C, CACNA1B GPBAR1 2298/4885PIK3CA 1471/4885CAMK1D 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback